The endothelial cell secretome as a novel treatment to prime adipose-derived stem cells for improved wound healing in diabetes

In the current climate of increasing diabetes rates, there exists a significant need for improved therapies for diabetic wounds. ASCs have exhibited improved wound healing in previous studies, but this benefit is known to be suppressed by hyperglycemia. Treating stem cells with the secreted protein cocktail of endothelial cells-secretomal priming-seems to overcome the inhibition of the diabetic state, making ASCs a viable treatment option for these wounds. Priming evidently induces endothelial differentiation of ASCs, thereby enhancing their involvement in angiogenesis. This study demonstrates the potential of these primed ASC-based therapies in vitro and in vivo and proposes several approaches by which they could be used in the clinical setting.